The Medical sector’s fourth-quarter earnings season is underway, with Johnson & Johnson exceeding expectations while Roche and Sanofi faced challenges due to currency headwinds. Overall, the sector is expected to see a 2.4% decrease in earnings but an 8.7% rise in sales compared to the previous year.

In the upcoming earnings reports, five drug/biotech companies, including Zoetis, Pacira BioSciences, Apellis Pharmaceuticals, Acadia Pharmaceuticals, and Denali Therapeutics, are predicted to beat expectations based on positive Earnings ESP and Zacks Rank.

Zoetis, with an Earnings ESP of +0.84% and a Zacks Rank #3, is expected to release its fourth-quarter results on February 12. The company has a history of beating estimates and is likely to see growth in companion animal product sales, offset by a decline in certain products.

Pacira BioSciences, Apellis Pharmaceuticals, Acadia Pharmaceuticals, and Denali Therapeutics also have positive Earnings ESP and Zacks Rank, indicating strong potential for positive results in their upcoming earnings reports. Each company has unique factors driving their expected performance in the fourth quarter.

Investors are eyeing quantum computing as the next technological revolution, with companies like Microsoft, Google, Amazon, and others racing to integrate this advanced technology. Senior Stock Strategist Kevin Cook highlights 7 top quantum stocks poised for success in his report, “Beyond AI: The Quantum Leap in Computing Power.”

Read more at Nasdaq: 5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates